KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study.Am J HematolPMID 39927501PMC119663522025-May0.98未发现恶性肿瘤人群证据。待处理
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39934055无 PMCID2025-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials.Ann Rheum DisPMID 39948001无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.Eur J HaematolPMID 39952901PMC119766852025-May0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks Trial.Am J OphthalmolPMID 39954920无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE.J Allergy Clin Immunol PractPMID 39956162无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents.J Child Adolesc PsychopharmacolPMID 39970021无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.Lancet RheumatolPMID 39983751无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials.Ann OncolPMID 39986927PMC120344802025-May0.90The record reports results from two randomized Phase III trials in human oncology with time-to-event endpoints. However, the intervention is non-drug (radiation dose escalation), and the analysis is a biomarker validation study, not a report of a drug-containing intervention. Therefore, it is excluded.已完成
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes Obes MetabPMID 39996356PMC119650272025-May0.98未发现恶性肿瘤人群证据。待处理
Cost-effectiveness of swab versus tissue sampling for infected diabetic foot ulcers from the CODIFI2 randomised controlled trial.Diabet Med已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other。PMID 40013389PMC120065562025-May0.98未发现恶性肿瘤人群证据。无 KM 图
iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies.Diabetes Obes MetabPMID 40013432PMC119649952025-May0.98未发现恶性肿瘤人群证据。待处理
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial.Lancet Respir MedPMID 40020692无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study).J Allergy Clin Immunol PractPMID 40023371无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Dupilumab reduces acute exacerbations and improves lung function in patients with COPD with type 2 inflammation irrespective of body mass index, airflow obstruction, dyspnea, and exercise capacity index scores.Respir MedPMID 40024335无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.Lancet Diabetes EndocrinolPMID 40031941无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
A Bayesian analysis of the VITAL trial: effects of ω-3 fatty acid supplementation on cardiovascular events.Am J Clin NutrPMID 40032221PMC121074942025-May0.98未发现恶性肿瘤人群证据。待处理
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.Nat MedPMID 40044930PMC128514172025-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
A Randomised, Double-Blind Trial to Compare the Efficacy, Safety, and Immunogenicity of the Biosimilar Ustekinumab FYB202 with Reference Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis.Adv TherPMID 40048101PMC120062712025-May0.98未发现恶性肿瘤人群证据。待处理
CODIFI2: Randomised controlled trial to compare clinical and cost-effectiveness of swabs versus tissue sampling to inform management of infected diabetic foot ulcers.Diabet MedPMID 40051068PMC120065542025-May0.98未发现恶性肿瘤人群证据。待处理
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.Nat MedPMID 40055521PMC120922582025-May0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV.AIDS BehavPMID 40063206PMC120319942025-May0.98未发现恶性肿瘤人群证据。待处理
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.Nat MedPMID 40065169PMC120922442025-May0.95The study is an eligible Phase III oncology RCT with drug intervention and original results, but the primary and key secondary endpoints are not time-to-event efficacy endpoints as required (they are response-based or continuous outcomes). Therefore, it is excluded from the KM digitization cohort.待处理
Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials.J DermatolPMID 40066907PMC120562802025-May0.95The study is a non-oncology (psoriasis) trial. Although it meets other criteria (phase 3, randomized, drug intervention, original results), it fails the fundamental oncology requirement for inclusion in this cohort.待处理
Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.Diabetes Obes MetabPMID 40069849PMC119649882025-May0.98未发现恶性肿瘤人群证据。待处理
Energy intake is associated with dietary macronutrient densities: inversely with protein and monounsaturated fat and positively with polyunsaturated fat and carbohydrate among postmenopausal females.Am J Clin NutrPMID 40088973PMC121074882025-May0.98未发现恶性肿瘤人群证据。待处理
Safety, Functional Disability, Healthcare Utilization, and Quality-of-Life Outcomes in Elderly Receiving Alteplase and Tenecteplase: A Secondary Analysis From the AcT Trial.StrokePMID 40123483无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Comparison of Local and Centrally Adjudicated Modified Rankin Scale Scores in the MOST Trial.StrokePMID 40123511PMC120373012025-May0.98未发现恶性肿瘤人群证据。待处理
Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.Nat MedPMID 40133524PMC129512982025-May0.98未发现恶性肿瘤人群证据。待处理
Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study.Adv TherPMID 40169529PMC120062582025-May0.98未发现恶性肿瘤人群证据。待处理
Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease.J Prev Alzheimers DisPMID 40189473PMC121840222025-May0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of brexpiprazole in adolescents with schizophrenia: a multicountry, randomised, double-blind, placebo-controlled, phase 3 trial with an active reference.Lancet PsychiatryPMID 40209740无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40220771无 PMCID2025-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial.Lancet HaematolPMID 40222370无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up.Lancet Child Adolesc HealthPMID 40246359无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40250457无 PMCID2025-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma.NEJM Evid疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40261119无 PMCID2025-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial.Cancer Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:瀑布图;FIGURE 2:森林图/亚组分析图;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图。PMID 40272146PMC120200262025-May0.95The record is a subgroup/ad hoc analysis from the Phase III NETTER-1 trial. While it meets most eligibility criteria (oncology, human, randomized, Phase III, drug intervention, time-to-event endpoints), it is not an original formal-result report of the main trial, which is required for inclusion. It is a secondary analysis focusing on tumor shrinkage as a predictor, not the primary or key secondary efficacy result report.无 KM 图
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.Expert Rev Clin ImmunolPMID 40296516无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.Lancet HaematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40306831无 PMCID2025-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.Lancet HaematolPMID 40306832无 PMCID2025-May0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Infant mental health services for birth and foster families of maltreated pre-school children in foster care (BeST?): a cluster-randomized phase 3 clinical effectiveness trial.Nat MedPMID 40312587PMC120922392025-May0.98未发现恶性肿瘤人群证据。待处理
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.Future Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 3.:非 KM 图;另有 1 张未列出。PMID 40331625PMC120774702025-May0.90The study is an exploratory analysis of patient-reported adverse events from the CASPIAN trial. While it originates from a Phase III randomized trial with a drug intervention, it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.). The focus is on safety/quality-of-life outcomes, which are excluded per criteria.无 KM 图
Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON.ESMO Open疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:森林图/亚组分析图;Figure 3:森林图/亚组分析图;Figure 4:森林图/亚组分析图;Figure 5:森林图/亚组分析图。PMID 40334315PMC121678832025-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials.JCO Clin Cancer InformPMID 40344545PMC123350102025-May0.85The record describes a prognostic analysis of an AI algorithm using data from Phase III randomized trials, but does not evaluate a drug intervention. It is an AI/diagnostic/prognostic study, not a drug efficacy trial.已完成
Lipid-Lowering Effect and Safety of Ezetimibe and Atorvastatin 5 mg in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-Blind, Parallel, Multicenter, Phase 3 Clinical Trial.Clin CardiolPMID 40357888PMC120702492025-May0.98未发现恶性肿瘤人群证据。待处理
Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial.Nephrology (Carlton)PMID 40369895PMC120790032025-May0.98未发现恶性肿瘤人群证据。待处理
Evaluation of mobile health technology combining telemonitoring and teleintervention versus usual care in vulnerable-phase heart failure management (HERMeS): a multicentre, randomised controlled trial.Lancet Digit HealthPMID 40374486无 PMCID2025-May0.98未发现恶性肿瘤人群证据。待处理
TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease.Alzheimers DementPMID 40390253PMC120890732025-May0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Efinaconazole 10% Topical Solution for Treatment of Onychomycosis in Older Adults: A Post Hoc Analysis of Two Phase 3 Randomised Trials.MycosesPMID 40396391PMC120934452025-May0.98未发现恶性肿瘤人群证据。待处理